London Allergy and Immunology Centre Ltd 07935559 false 2023-02-03 2024-02-02 2024-02-02 The principal activity of the company is Specialist Medical Practice Digita Accounts Production Advanced 6.30.9574.0 true true 07935559 2023-02-03 2024-02-02 07935559 2024-02-02 07935559 core:RetainedEarningsAccumulatedLosses 2024-02-02 07935559 core:ShareCapital 2024-02-02 07935559 core:CurrentFinancialInstruments core:WithinOneYear 2024-02-02 07935559 core:FurnitureFittingsToolsEquipment 2024-02-02 07935559 core:LandBuildings 2024-02-02 07935559 core:MotorVehicles 2024-02-02 07935559 bus:SmallEntities 2023-02-03 2024-02-02 07935559 bus:AuditExemptWithAccountantsReport 2023-02-03 2024-02-02 07935559 bus:AbridgedAccounts 2023-02-03 2024-02-02 07935559 bus:SmallCompaniesRegimeForAccounts 2023-02-03 2024-02-02 07935559 bus:RegisteredOffice 2023-02-03 2024-02-02 07935559 bus:CompanySecretaryDirector1 2023-02-03 2024-02-02 07935559 bus:OrdinaryShareClass1 bus:CumulativeShares 2023-02-03 2024-02-02 07935559 bus:PrivateLimitedCompanyLtd 2023-02-03 2024-02-02 07935559 bus:Agent1 2023-02-03 2024-02-02 07935559 core:RetainedEarningsAccumulatedLosses 2023-02-03 2024-02-02 07935559 core:ShareCapital 2023-02-03 2024-02-02 07935559 core:FurnitureFittingsToolsEquipment 2023-02-03 2024-02-02 07935559 core:LandBuildings 2023-02-03 2024-02-02 07935559 core:MotorVehicles 2023-02-03 2024-02-02 07935559 core:OfficeEquipment 2023-02-03 2024-02-02 07935559 countries:AllCountries 2023-02-03 2024-02-02 07935559 dpl:AdministrativeExpenses 2023-02-03 2024-02-02 07935559 dpl:CostSales 2023-02-03 2024-02-02 07935559 2023-02-02 07935559 core:RetainedEarningsAccumulatedLosses 2023-02-02 07935559 core:ShareCapital 2023-02-02 07935559 core:FurnitureFittingsToolsEquipment 2023-02-02 07935559 core:LandBuildings 2023-02-02 07935559 core:MotorVehicles 2023-02-02 07935559 2022-02-03 2023-02-02 07935559 2023-02-02 07935559 core:CurrentFinancialInstruments core:WithinOneYear 2023-02-02 07935559 core:FurnitureFittingsToolsEquipment 2023-02-02 07935559 core:LandBuildings 2023-02-02 07935559 core:MotorVehicles 2023-02-02 07935559 bus:OrdinaryShareClass1 bus:CumulativeShares 2022-02-03 2023-02-02 07935559 core:RetainedEarningsAccumulatedLosses 2022-02-03 2023-02-02 07935559 core:ShareCapital 2022-02-03 2023-02-02 07935559 dpl:AdministrativeExpenses 2022-02-03 2023-02-02 07935559 dpl:CostSales 2022-02-03 2023-02-02 07935559 2022-02-02 07935559 core:RetainedEarningsAccumulatedLosses 2022-02-02 07935559 core:ShareCapital 2022-02-02 iso4217:GBP xbrli:pure

Registration number: 07935559

London Allergy and Immunology Centre Ltd

Annual Report and Unaudited Abridged Financial Statements

for the Year Ended 2 February 2024

 

London Allergy and Immunology Centre Ltd

Contents

Company Information

1

Director's Report

2

Accountants' Report

3

Abridged Profit and Loss Account

4

Statement of Comprehensive Income

5

Abridged Balance Sheet

6

Statement of Changes in Equity

7

Notes to the Unaudited Abridged Financial Statements

8 to 12

iXBRL Detailed Profit and Loss Account

13

 

London Allergy and Immunology Centre Ltd

Company Information

Director

Mr Michael Rudenko

Company secretary

Mr Michael Rudenko

Registered office

9 Harley Street
London
W1G 9QY

Accountants

Simon Kingsley
58 Montague Road
Hackney
London
E8 2HW

 

London Allergy and Immunology Centre Ltd

Director's Report for the Year Ended 2 February 2024

The director presents his report and the abridged financial statements for the year ended 2 February 2024.

Director of the company

The director who held office during the year was as follows:

Mr Michael Rudenko - Company secretary and director

Principal activity

The principal activity of the company is Specialist Medical Practice

Small companies provision statement

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the director on 30 October 2024
 

.........................................
Mr Michael Rudenko
Company secretary and director

 

Chartered Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
London Allergy and Immunology Centre Ltd
for the Year Ended 2 February 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of London Allergy and Immunology Centre Ltd for the year ended 2 February 2024 as set out on pages 4 to 12 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of London Allergy and Immunology Centre Ltd, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of London Allergy and Immunology Centre Ltd and state those matters that we have agreed to state to the Board of Directors of London Allergy and Immunology Centre Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than London Allergy and Immunology Centre Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that London Allergy and Immunology Centre Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of London Allergy and Immunology Centre Ltd. You consider that London Allergy and Immunology Centre Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of London Allergy and Immunology Centre Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Simon Kingsley
58 Montague Road
Hackney
London
E8 2HW

30 October 2024

 

London Allergy and Immunology Centre Ltd

Abridged Profit and Loss Account for the Year Ended 2 February 2024

Note

2024
£

2023
£

Gross profit

 

785,043

635,057

Administrative expenses

 

(464,334)

(176,904)

Other interest receivable and similar income

 

18,117

4,216

Profit before tax

4

338,826

462,369

Tax on profit

 

(78,256)

(85,418)

Profit for the financial year

 

260,570

376,951

The above results were derived from continuing operations.

The company has no recognised gains or losses for the year other than the results above.

 

London Allergy and Immunology Centre Ltd

Statement of Comprehensive Income for the Year Ended 2 February 2024

2024
£

2023
£

Profit for the year

260,570

376,951

Total comprehensive income for the year

260,570

376,951

 

London Allergy and Immunology Centre Ltd

(Registration number: 07935559)
Abridged Balance Sheet as at 2 February 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

5

922,994

853,084

Current assets

 

Cash at bank and in hand

 

2,235,992

2,110,452

Creditors: Amounts falling due within one year

(168,417)

(196,037)

Net current assets

 

2,067,575

1,914,415

Net assets

 

2,990,569

2,767,499

Capital and reserves

 

Called up share capital

7

100

100

Retained earnings

2,990,469

2,767,399

Shareholders' funds

 

2,990,569

2,767,499

For the financial year ending 2 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the director on 30 October 2024
 

.........................................

Mr Michael Rudenko

Company secretary and director

 

London Allergy and Immunology Centre Ltd

Statement of Changes in Equity for the Year Ended 2 February 2024

Share capital
£

Retained earnings
£

Total
£

At 3 February 2023

100

2,767,399

2,767,499

Profit for the year

-

260,570

260,570

Dividends

-

(37,500)

(37,500)

At 2 February 2024

100

2,990,469

2,990,569

Share capital
£

Retained earnings
£

Total
£

At 3 February 2022

100

2,428,448

2,428,548

Profit for the year

-

376,951

376,951

Dividends

-

(38,000)

(38,000)

At 2 February 2023

100

2,767,399

2,767,499

 

London Allergy and Immunology Centre Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 2 February 2024

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
9 Harley Street
London
W1G 9QY
England

These financial statements were authorised for issue by the director on 30 October 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

London Allergy and Immunology Centre Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 2 February 2024

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office Equipment

33% on Straight line basis

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

London Allergy and Immunology Centre Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 2 February 2024

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 2 (2023 - 2).

4

Profit before tax

Arrived at after charging/(crediting)

2024
£

2023
£

Depreciation expense

29,639

4,170

5

Tangible assets

Land and buildings
£

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost or valuation

At 3 February 2023

844,619

16,964

-

861,583

Additions

6,456

43,253

49,840

99,549

At 2 February 2024

851,075

60,217

49,840

961,132

Depreciation

At 3 February 2023

-

8,499

-

8,499

Charge for the year

-

19,871

9,768

29,639

At 2 February 2024

-

28,370

9,768

38,138

Carrying amount

At 2 February 2024

851,075

31,847

40,072

922,994

At 2 February 2023

844,619

8,465

-

853,084

Included within the net book value of land and buildings above is £851,075 (2023 - £844,619) in respect of freehold land and buildings.
 

6

Debtors

Debtors includes £Nil (2023 - £Nil) due after more than one year.

 

London Allergy and Immunology Centre Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 2 February 2024

7

Share capital

8

Dividends

Interim dividends paid

2024
£

2023
£

Interim dividend of £375.00 (2023 - £380.00) per each Ordinary

37,500

38,000

 

 

9

Related party transactions

 

London Allergy and Immunology Centre Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 2 February 2024

Director's remuneration

The director's remuneration for the year was as follows:

2024
£

2023
£

Remuneration

11,900

12,750

Contributions paid to money purchase schemes

98,000

-

109,900

12,750

 

London Allergy and Immunology Centre Ltd

iXBRL Detailed Profit and Loss Account for the Year Ended 2 February 2024

2024
£

2023
£

Turnover/revenue

1,064,609

873,694

Cost of sales

Opening stock/inventories

-

-

Purchase of raw materials and consumables

(279,566)

(238,637)

Closing stock/inventories

-

-

Gross profit

785,043

635,057

Distribution costs

Administrative expenses

Audit and accountancy other services

(1,100)

(1,496)

Rent, rates and services costs

(23,221)

(28,708)

Utilities costs

(7,297)

(8,607)

Other repairs and maintenance costs

(84,329)

(20,708)

Depreciation of fixed assets

(29,639)

(4,170)

Wages and salaries excluding directors

(12,000)

(12,000)

Pension costs defined contribution schemes excluding directors

(100,000)

-

Staff costs excluding directors

(112,000)

(12,000)

Salaries and fees, directors

(11,900)

(12,750)

Company contributions to money purchase plans, directors

(98,000)

-

Staff costs, directors

(109,900)

(12,750)

Travel and subsistence

(62,555)

(64,419)

Legal and professional costs

(11,946)

(2,400)

Insurance costs

(2,391)

(2,234)

Charitable donations

(2,005)

(6,020)

Other costs

(17,951)

(13,392)

Other operating income

Other items

Profit on ordinary activities before finance charges and interest

320,709

458,153

Bank interest and similar income receivable

18,117

4,216

Profit on ordinary activities before taxation

338,826

462,369

Tax on profit or loss on ordinary activities

(78,256)

(85,418)

Profit for the financial year

260,570

376,951